Keywords: Merck & Co, AVEO Pharma, Johnson & Johnson, Janssen, AV-299, Caelyx, Ling cancer, Returns rights

Merck & Co returns rights to HGF antibody candidate to AVEO Pharma and Caeylx to Johnson & Johnson

Article | 01 October 2010

Print This

As part of its R&D pipeline portfolio review since it acquired fellow USA-based Schering-Plough last year, US drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in